What Do We Know About Clinical Trial Accessibility and Participation Barriers? A Science-Based Overview

Image generated by AI

Every year, thousands of promising medical treatments languish in development because researchers cannot find enough people willing to participate in the studies that would bring them to patients. This paradox—where lifesaving therapies remain trapped in labs while millions suffer from untreated diseases—sits at the heart of modern medicine’s most vexing problem. Clinical trials, the gold standard through which we validate whether new drugs and therapies actually work, are increasingly starved for participants, with enrollment failures accounting for the termination of an estimated 50% of clinical trials before completion.

The barriers preventing people from joining these trials are far more complex than simple unwillingness. Geographic isolation, financial hardship, systemic distrust born from historical medical racism, lack of awareness, competing work and family obligations, and the profound inconvenience of repeated clinic visits create a perfect storm that excludes vast swaths of the population from shaping the medicines they will eventually take. Understanding these barriers and developing solutions to overcome them has become critical not just for accelerating drug development, but for ensuring that the medicines we create actually work across diverse populations—not just the narrow demographics that end up in early trials.

What Is Clinical Trial Accessibility and Participation Barriers?

Clinical trial accessibility and participation barriers refer to the structural, financial, social, and systemic obstacles that prevent people from enrolling in and completing clinical research studies. A clinical trial is a research study in which human volunteers test new medical interventions—drugs, devices, behavioral therapies, or preventive strategies—to determine their safety and effectiveness before they can be approved for widespread use. Participation barriers are the factors that make it difficult or impossible for eligible individuals to enroll in these studies, whether they stem from the design of the trial itself, the location where it takes place, the demands it places on participants, or broader societal inequalities that affect certain populations disproportionately.

The modern clinical trial system emerged in its current form following World War II, shaped by the Nuremberg Code of 1947, which established fundamental principles of informed consent after Nazi medical experimentation atrocities came to light. Throughout the 1950s and 1960s, the structure of clinical trials became increasingly standardized through regulatory frameworks like the Declaration of Helsinki and the establishment of Institutional Review Boards. However, for decades, the focus remained almost exclusively on scientific rigor and statistical validity, with far less attention paid to ensuring that trials could actually recruit and retain diverse populations of participants—a blind spot that persists in many quarters today.

What the Research Shows

The mechanisms underlying trial participation barriers operate at multiple levels simultaneously. At the individual level, people face practical constraints: time away from work means lost wages they cannot afford, transportation to distant research centers strains limited resources, and the physical or cognitive burden of repeated visits and tests becomes prohibitive for those managing chronic illnesses or disabilities. At the community level, historical trauma—particularly the Tuskegee syphilis study and other instances of medical exploitation—has created justified skepticism toward research institutions, especially among Black Americans and other marginalized groups. At the structural level, trial eligibility criteria are often so restrictive that they exclude the very people most affected by a disease; strict inclusion and exclusion rules designed to create homogeneous study populations for cleaner data inadvertently eliminate older adults, people with multiple chronic conditions, pregnant women, and racial and ethnic minorities from the very research meant to develop treatments for them.

Consider a concrete example: a clinical trial for a new heart failure treatment might require participants to visit the research center every two weeks for six months, with each visit lasting three hours. For someone working an hourly wage job in a rural area, two hours of driving time plus six hours of lost work per month amounts to a significant financial burden—perhaps $600 to $800 monthly that they simply cannot absorb. Add to this the reality that the trial may only enroll participants with very specific baseline characteristics, excluding anyone with kidney disease or diabetes, conditions that often coincide with heart failure in real-world populations. The result is a study that generates pristine data but tells us nothing about whether the treatment works for most people who actually have the disease.

What This Means for Patients and Science

The practical consequences of limited trial accessibility are profound and measurable. When clinical trials exclude large segments of the population, the resulting drugs are tested almost exclusively on populations that are whiter, wealthier, healthier, and often younger than the general population that will eventually use them. This creates a scientific blind spot: we simply do not know how treatments perform across the diversity of real human bodies and life circumstances. Women have historically been underrepresented in trials, meaning many medications have been inadequately studied for how they work in female bodies—a gap that has contributed to women being diagnosed with heart disease at later, more severe stages because symptoms present differently than what was observed in male-dominated trial populations. Similarly, older adults, who consume the majority of medications, have long been excluded from early-phase trials, leaving crucial questions about drug interactions and age-related metabolism unanswered.

Real-world medical applications reveal the stakes of this problem. The FDA’s approval of new cancer drugs, cardiovascular therapies, and psychiatric medications proceeds based on trial data that systematically overrepresents certain populations. Pharmaceutical companies face declining returns on investment as recruitment challenges balloon trial timelines and costs—the average cost of bringing a new drug to market has ballooned to nearly $2.6 billion, in part because of recruitment inefficiencies. Beyond pharmaceuticals, medical device companies, academic medical centers conducting treatment research, and vaccine developers all struggle with the same accessibility barriers. The COVID-19 pandemic exposed this vulnerability sharply: initial vaccine trials had recruitment challenges in minority communities, partly due to historic distrust and partly due to practical barriers, yet these communities were disproportionately affected by the disease they had been excluded from helping study.

Recent Breakthroughs in Clinical Trial Accessibility and Participation Barriers

The last three years have witnessed a significant shift in how the biomedical research community approaches trial accessibility. In 2022, the FDA issued guidance emphasizing the importance of recruiting diverse populations into clinical trials and explicitly encouraging sponsors to remove unnecessary exclusion criteria that reduce generalizability without improving scientific validity. Simultaneously, the rise of decentralized clinical trials—studies where participants complete visits at home or at local clinics rather than traveling to centralized research centers—has demonstrated measurable improvements in enrollment and retention. Companies and academic institutions have begun deploying mobile clinics, telehealth platforms, and community health worker networks to bring trials closer to patients rather than expecting patients to come to trials. These digital-first approaches have shown promise in dramatically reducing barriers, particularly for patients with mobility limitations or those in rural areas.

Researchers are currently investigating how community engagement models can rebuild trust between marginalized populations and research institutions. Several academic medical centers now employ community advisory boards—groups of people from the local population affected by a disease who actively shape trial design from the beginning, ensuring that eligibility criteria make sense, visit schedules are feasible, and recruitment messaging resonates authentically. The question occupying researchers now is how to scale these approaches and make them standard practice rather than exceptional. Another frontier involves using real-world data—information gathered from electronic health records, insurance claims, and patient registries—to supplement or even partially replace traditional trial designs, potentially making research less burdensome while capturing more representative populations.

Why Clinical Trial Accessibility and Participation Barriers Matters for the Future

As medicine increasingly recognizes that one-size-fits-all approaches to treatment are inadequate, the diversity and representativeness of clinical trial populations becomes not merely a matter of equity but of scientific validity. Precision medicine—the emerging paradigm of tailoring treatments based on individual genetic, environmental, and lifestyle factors—cannot function without trial data that captures this diversity. If we continue to test treatments predominantly in narrow populations, precision medicine risks becoming only precise for those populations, widening rather than narrowing health disparities. Furthermore, as clinical research expands into areas like digital therapeutics, artificial intelligence-assisted diagnosis, and complex behavioral interventions, the barriers to participation change in character and require new solutions.

Yet substantial challenges remain. Addressing trial accessibility requires not just logistical innovation but systemic change across academic institutions, regulatory agencies, and pharmaceutical companies—change that requires time, investment, and sometimes uncomfortable reckoning with institutional racism and structural inequity. Many researchers still view diversity recruitment as an add-on or burden rather than integral to good science. The financial incentive structures in pharmaceutical development still reward speed-to-market over representativeness. And while decentralized trials and digital approaches offer promise, they introduce new equity problems, potentially excluding people without reliable internet access or digital literacy. These contradictions mean that solving the accessibility puzzle will require sustained effort across multiple fronts simultaneously.

Key Takeaways

• Clinical trial participation barriers prevent roughly half of all trials from completing successfully and result in medicines tested predominantly on narrow populations that do not represent the diversity of people who will eventually use them.
• Barriers operate through interconnected mechanisms: practical constraints like transportation and time costs, historical medical trauma creating justified distrust, and overly restrictive eligibility criteria designed for statistical purity rather than real-world applicability.
• The most promising recent innovations include decentralized trials that move research to patients’ homes and communities, community advisory boards that shape trial design from the ground up, and efforts to incorporate real-world data into research protocols.
• Current research shows that with intentional design changes and community engagement, trial enrollment and retention can improve dramatically, while simultaneously improving the scientific validity and generalizability of results.
• Solving clinical trial accessibility is foundational to the future of precision medicine and equitable healthcare—without diverse trial populations, we cannot understand how treatments work across the full spectrum of human diversity.